ACAD
48.81
+0.99
+2.07%
AEMD
9.99
+0.19
+1.94%
APRI
1.44
+0.01
+0.70%
ARNA
4.04
+0.07
+1.76%
ATEC
1.36
0.00
0.00%
CNAT
4.74
-0.08
-1.66%
CRXM
0.3
0.00
0.00%
CYTX
0.44
+0.01
+2.33%
DXCM
84.65
+0.73
+0.87%
GNMK
8.5
+0.02
+0.24%
HALO
23.34
+0.21
+0.91%
ILMN
219.3
+0.43
+0.20%
INNV
0.155
0.00
0.00%
INO
7.29
+0.08
+1.11%
ISCO
0.043
0.00
0.00%
ISIS
54.93
+1.76
+3.31%
LGND
108.26
+0.48
+0.45%
LPTN
0.27
0.00
+0.15%
MBVX
2.16
+0.21
+10.77%
MEIP
1.56
-0.04
-2.50%
MNOV
3.75
+0.06
+1.63%
MRTX
28.61
+1.11
+4.04%
MSTX
0.447
0.00
-0.0447%
NBIX
50.12
+0.1
+0.20%
NUVA
55.01
+0.08
+0.15%
ONCS
6.06
-0.04
-0.66%
ONVO
3.38
+0.01
+0.30%
OREX
4
+0.05
+1.27%
OTIC
25.77
+0.26
+1.02%
QDEL
20.71
-0.25
-1.19%
RCPT
227.86
+0.38
+0.17%
RGLS
8.2
-0.06
-0.73%
RMD
57.95
+1.83
+3.26%
SCIE
0.018
-0.002
-10.000%
SPHS
0.87
-0.01
-1.1818%
SRNE
20.78
+0.39
+1.91%
TROV
7.88
+0.07
+0.90%
VICL
0.644
+0.014
+2.222%
ZGNX
19.31
0.00
0.00%
ACAD
48.81
+0.99
+2.07%
AEMD
9.99
+0.19
+1.94%
APRI
1.44
+0.01
+0.70%
ARNA
4.04
+0.07
+1.76%
ATEC
1.36
0.00
0.00%
CNAT
4.74
-0.08
-1.66%
CRXM
0.3
0.00
0.00%
CYTX
0.44
+0.01
+2.33%
DXCM
84.65
+0.73
+0.87%
GNMK
8.5
+0.02
+0.24%
HALO
23.34
+0.21
+0.91%
ILMN
219.3
+0.43
+0.20%
INNV
0.155
0.00
0.00%
INO
7.29
+0.08
+1.11%
ISCO
0.043
0.00
0.00%
ISIS
54.93
+1.76
+3.31%
LGND
108.26
+0.48
+0.45%
LPTN
0.27
0.00
+0.15%
MBVX
2.16
+0.21
+10.77%
MEIP
1.56
-0.04
-2.50%
MNOV
3.75
+0.06
+1.63%
MRTX
28.61
+1.11
+4.04%
MSTX
0.447
0.00
-0.0447%
NBIX
50.12
+0.1
+0.20%
NUVA
55.01
+0.08
+0.15%
ONCS
6.06
-0.04
-0.66%
ONVO
3.38
+0.01
+0.30%
OREX
4
+0.05
+1.27%
OTIC
25.77
+0.26
+1.02%
QDEL
20.71
-0.25
-1.19%
RCPT
227.86
+0.38
+0.17%
RGLS
8.2
-0.06
-0.73%
RMD
57.95
+1.83
+3.26%
SCIE
0.018
-0.002
-10.000%
SPHS
0.87
-0.01
-1.1818%
SRNE
20.78
+0.39
+1.91%
TROV
7.88
+0.07
+0.90%
VICL
0.644
+0.014
+2.222%
ZGNX
19.31
0.00
0.00%
Home » Archive by Category

Xconomy

Gene Therapy’s Rebirth Continues With Bristol, UniQure Cardio Deal

April 6, 2015 – 6:19 am

There’s no doubt at this point that gene therapy research, after a decade proceeding in relative obscurity, is back. A host of companies are racing to find the best way to harness the science to…

[[Click headline to continue reading.]]

Gene Therapy’s Rebirth Continues With Bristol, UniQure Cardio Deal

April 6, 2015 – 6:19 am

There’s no doubt at this point that gene therapy research, after a decade proceeding in relative obscurity, is back. A host of companies are racing to find the best way to harness the science to…

[[Click headline to continue reading.]]

Academia vs. BioPharma: Young Scientists Between A Rock and A Hard Place

April 6, 2015 – 12:00 am

I’ve reached the stage of my career where I’ve been invited to give “career retrospective talks” to grad students and post-docs at academic institutions. It’s been an interesting and enjoyable…

[[Click headline to continue reading.]]

Academia vs. BioPharma: Young Scientists Between A Rock and A Hard Place

April 6, 2015 – 12:00 am

I’ve reached the stage of my career where I’ve been invited to give “career retrospective talks” to grad students and post-docs at academic institutions. It’s been an interesting and enjoyable…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Auspex, Hyperion, NuVasive, & More

April 2, 2015 – 1:19 pm

Xconomy national biotech editor Alex Lash is out wandering in the desert this week, so I’m stepping in as drover, and as biotech herds go, the one I’m rounding up today covers a lot of…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Auspex, Hyperion, NuVasive, & More

April 2, 2015 – 1:19 pm

Xconomy national biotech editor Alex Lash is out wandering in the desert this week, so I’m stepping in as drover, and as biotech herds go, the one I’m rounding up today covers a lot of…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Auspex, Hyperion, NuVasive, & More

April 2, 2015 – 1:19 pm

Xconomy national biotech editor Alex Lash is out wandering in the desert this week, so I’m stepping in as drover, and as biotech herds go, the one I’m rounding up today covers a lot of…

[[Click headline to continue reading.]]

NuVasive CEO Resigns After Probe of Personnel and Policy Violations

April 1, 2015 – 11:50 am

San Diego-based NuVasive (NASDAQ: NUVA), which makes specialized surgical products for use in spinal surgery, said today that chairman and CEO Alex Lukianov has resigned over violations of the…

[[Click headline to continue reading.]]

NuVasive CEO Resigns After Probe of Personnel and Policy Violations

April 1, 2015 – 11:50 am

San Diego-based NuVasive (NASDAQ: NUVA), which makes specialized surgical products for use in spinal surgery, said today that chairman and CEO Alex Lukianov has resigned over violations of the…

[[Click headline to continue reading.]]

Equity Crowdfunding Backers Clash Over Fundraising Limits in States

April 1, 2015 – 8:29 am

After five years of bootstrapping his startup, Instancy, Harvey Singh’s company has a finished education software product, revenue, and a growing roster of employees. As Singh looks overseas to…

[[Click headline to continue reading.]]